- Home
- CWEN vs LGND Comparison
CWEN vs LGND Comparison
Compare CWEN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | LGND |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | 60 | 68 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CWEN | LGND |
|---|---|---|
| Price | $38.21 | $202.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $41.25 | ★ $245.00 |
| AVG Volume (30 Days) | ★ 870.0K | 162.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.19 | $0.74 |
| Revenue Next Year | $7.78 | $19.04 |
| P/E Ratio | ★ $17.06 | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.63 | $93.58 |
| 52 Week High | $41.51 | $227.92 |
Technical Indicators
Market Signals| Indicator | CWEN | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 50.68 |
| Support Level | $31.51 | $198.52 |
| Resistance Level | $41.51 | $207.72 |
| Average True Range (ATR) | 1.00 | 10.61 |
| MACD | -0.18 | 1.20 |
| Stochastic Oscillator | 60.00 | 45.50 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.